pyrimidine has been researched along with Lymphoma, Mantle-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, J; Liu, M; Liu, Y; Ran, F; Tang, W; Wang, P; Zhang, D; Zhao, G | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
2 other study(ies) available for pyrimidine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Lymphoma, Mantle-Cell; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2019 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |